Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding the vesting and lapsing of share options granted under the 2009 GlaxoSmithKline Share Option Plan (SOP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation transactions and does not contain consolidated financial statements or operational metrics.
Material Changes
The primary material change reported is the lapse of conditional share options granted in 2009. The Company failed to achieve the Earnings Per Share (EPS) performance condition for the three-year period ending December 31, 2011. Consequently, 50% of the options granted to Executive Directors and PDMRs lapsed on February 17, 2012. Conversely, a separate tranche of options granted to senior executives (now PDMRs) that were not subject to performance conditions became exercisable on the same date.
Outlook, Risks, and Management Commentary
Management commentary is limited to the Remuneration Committee's confirmation of the option lapses and vestings. The filing notes that the remaining 50% of the 2009 options, subject to a four-year performance period ending December 31, 2012, will be assessed in February 2013. No specific guidance, forward-looking financial outlook, or discussion of general business risks is included in this specific notification.
Important Facts for Investors to Verify
- Performance Failure: Verify the specific EPS targets missed for the 2009-2011 period that triggered the lapse of options for Executive Directors and PDMRs.
- Option Lapse Volume: Confirm the total number of lapsed options (Ordinary Shares and ADSs) across all listed executives, totaling significant equity dilution avoidance.
- Future Vesting: Monitor the upcoming assessment in February 2013 for the remaining 2009 options tied to the four-year performance period.
- Exercisable Options: Note that options for Mr. P Thomson, Dr. P Vallance, and Mrs. V Whyte became exercisable on February 17, 2012, at a price of £11.77.